Any current/future new fundraising through debt or equity?

The transcript does not mention any current or planned fundraising activities through debt or equity. There is no discussion about issuing new shares, taking on additional debt, or related capital raising plans. The focus is primarily on growth strategies, cost management, productivity, and operational performance. Questions from analysts and investors mainly relate to growth prospects, margins, competition, manufacturing, and advertising spends. Therefore, no indication of new fundraising initiatives was provided in this call.

Any current/future capex/capital investment/strategic investment?

The company plans to continue increasing local manufacturing but large-scale investments in technologically advanced premium systems require justified scale and growth prospects. A substantial portion of sales are already locally manufactured, with ongoing efforts to bring more business segments under local manufacturing. Capital investments for manufacturing premium products like men's grooming systems depend on potential scale and growth. No specific current or future capex figures were disclosed, but focus remains on strategic investments to support growth and innovation. The company is foc

Future growth expectations in sales/revenue/volumes?

Volume consumption growth within FMCG is expected to be mid-single digits over the next 5-7 years. Certain underdeveloped categories have potential for double-digit growth. Oral care category projected to grow mid-single digits in line with FMCG market growth. The company aims to grow faster than the oral care category by expanding consumer base. Consistent double-digit topline and bottom-line growth delivered over past three years. Market share growth accelerated post-COVID, reaching record levels. Growth driven by premiumization, pricing strategies, and cost-reduction programs.

Future growth expectations in earnings/operating earnings/profits/EPS?

The company aims to continue driving both topline and bottom-line growth, with an ambition to grow bottom-line ahead of topline in the foreseeable future. Exact margin or profit bands are difficult to predict, but the focus remains on funding innovation, raising product superiority, and absorbing macroeconomic headwinds. Operating profit margin has improved by 830 basis points over the past decade. Profit has more than quadrupled over the past 10 years, showing consistent superior execution. For the fiscal year 22/23, sales grew 10% and profit grew strongly at 18%, driven by premiumiza

Gillette IndiaQ1 FY24Personal Products

Gillette India Q1 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹7,077P/E: 34.5Market Cap: ₹23.1K CrSector: Personal Products

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

Volume consumption growth within FMCG is expected to be mid-single digits over the next 5-7 years.
Certain underdeveloped categories have potential for double-digit growth.
Oral care category projected to grow mid-single digits in line with FMCG market growth.
The company aims to grow faster than the oral care category by expanding consumer base.
Consistent double-digit topline and bottom-line growth delivered over past three years.
Market share growth accelerated post-COVID, reaching record levels.
Growth driven by premiumization, pricing strategies, and cost-reduction programs.
Expansion of direct reach by over 65% in past five years supports growth.
Integrated growth strategies focus on category growth alongside market share gains.
The company is cautiously optimistic due to inflation and external variables like rainfall impacting consumption.

Margin guidance

Category 3

The company aims to continue driving both topline and bottom-line growth, with an ambition to grow bottom-line ahead of topline in the foreseeable future.
Exact margin or profit bands are difficult to predict, but the focus remains on funding innovation, raising product superiority, and absorbing macroeconomic headwinds.
Operating profit margin has improved by 830 basis points over the past decade.
Profit has more than quadrupled over the past 10 years, showing consistent superior execution.
For the fiscal year 22/23, sales grew 10% and profit grew strongly at 18%, driven by premiumization, pricing strategies, and cost-reduction programs.
Commodity price volatility suggests margin recovery will take longer than 9-12 months, indicating cautious optimism on near-term margin expansion.
Dividend per share has nearly tripled over 10 years, reflecting strong shareholder value creation.

See what Gillette India management said on margin guidance — free account, 30 seconds.

Fundraise plans

The transcript does not mention any current or planned fundraising activities through debt or equity.
There is no discussion about issuing new shares, taking on additional debt, or related capital raising plans.
The focus is primarily on growth strategies, cost management, productivity, and operational performance.
Questions from analysts and investors mainly relate to growth prospects, margins, competition, manufacturing, and advertising spends.
Therefore, no indication of new fundraising initiatives was provided in this call.

Order book

Yes

The provided transcript from the Gillette India Limited Investors & Analysts Call does not mention or provide any information regarding the current or expected order book or pending orders. The discussion mainly focuses on: - Growth strategies (topline, bottom-line, category growth) - Market share and competition, including from D2C players - Commodity price impacts on margins - Manufacturing plans and local production - Advertising spend and productivity programs - Product portfolio and category outlook (grooming, oral care, appliances) - Use of AI/ML in distribution and retail execution - Shareholder value creation and financial performance No details or figures related to order book or pending orders were disclosed in the transcript.

See what Gillette India management said on order book — free account, 30 seconds.

Capex plans

Yes

The company plans to continue increasing local manufacturing but large-scale investments in technologically advanced premium systems require justified scale and growth prospects.
A substantial portion of sales are already locally manufactured, with ongoing efforts to bring more business segments under local manufacturing.
Capital investments for manufacturing premium products like men's grooming systems depend on potential scale and growth.
No specific current or future capex figures were disclosed, but focus remains on strategic investments to support growth and innovation.
The company is focused on driving productivity to fund superiority and absorb macro headwinds, implying efficient capital usage.
No direct mention of new strategic investments beyond manufacturing and productivity initiatives was made in the transcript.

Track Gillette India — get its next earnings analysis in your feed

How does Gillette India rank vs peers in Personal Products?

Pro feature

ThisGillette India

Rev 3Mar 3

See where Gillette India sits in Personal ProductsSee which companies these are, and every other name in the sector.Open rankings

How does Gillette India rank in Personal Products?

Compare Gillette India against every Personal Products company (Q1 FY24) on revenue, margins and earnings-call signals.

View Personal Products leaderboard →

What Gillette India's management said in earlier quarters

Others in Personal Products this season

Aakaar Medical (Q2 FY27)
Revenue from operations in H1 FY27: INR 43.72 Cr, up 72.6% YoY from INR 25.32 Cr in H1 FY26 (Page 12, 11, 4) . Key investor presentation takeaways from Aakaar M
Recode Studios Ltd (Q4 FY26)
The company plans to sustain marketing spends at about 20% of revenue to support growth and brand visibility, implying continued focus on operating profits…
Godrej Consumer Products Ltd (Q2 FY27)
Consolidated net sales for Q2 FY2027: ₹4,396 crore, up 19% year-on-year; constant currency growth 15% (Page 8) . Key investor presentation takeaways from Godrej
Colgate-Palmolive (India) Ltd (Q2 FY27)
1,692 crore, up 12.2% year-on-year from Rs. Key results statement takeaways from Colgate-Palmolive (India) Ltd's Q2 FY27 results statement — and how it ranks ag

Compare:vs Godrej Consumer Products Ltd vs Dabur India Ltd vs Cupid Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Gillette India Q1 FY24 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Gillette India rank in Personal Products?

Continue your research

What Gillette India's management said in earlier quarters

Others in Personal Products this season